Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ARTELO BIOSCIENCES INC (ARTL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.12-6.83%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ARTL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS loss improves from -$9.84 in 2026 to less negative | A supporting condition in ARTELO BIOSCIENCES INC's published investment case. The stated target is EPS loss improves to > -$5.28 in 2027. | Broken | EPS loss worsens or remains below -$5.28 in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ARTL is a high-risk, loss-making clinical-stage Healthcare business, so its multi-year view depends on pipeline progress and better financial execution. The thesis is marked intact, but confidence is low and management progress on reducing losses and negative cash flow has been limited.
The evidence gives no valuation or expectations data, so whether ARTL looks cheap, fair, or expensive versus peers cannot be assessed. The current evidence does show persistent losses and recent equity and debt financing activity, but it does not establish what the market already assumes about these risks.
Near term, earnings-miss risk is elevated, with a stated 64% miss probability, reflecting the smaller company size and erratic recent surprises. Across the multi-year view, operating losses and negative cash flow remain unresolved, while management’s pipeline focus includes ART27.13 and ART26.12; evidence of clinical delivery is limited. The Healthcare sector backdrop has strengthened, but weakening jobs data or poorer results from sector bellwethers could erode that support.
The thesis depends on whether management can make progress on losses and cash use while advancing ART27.13 and ART26.12. A continuing Healthcare sector tailwind would support the backdrop, while weaker employment data or misses and lower guidance from VRTX, REGN, or MRNA would be warning signs. Further equity or debt offerings also remain a funding factor to watch.
Over the next 1 to 3 years, ARTL’s long-term thesis is intact but fragile: pipeline execution and financial improvement matter more than the current sector tailwind, and the evidence remains limited. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company advances clinical programs while controlling cash flow losses around -$3.5M in Q3 2025. |
| Broken |
| cash from operations falls below -$3.5M per quarter |
Cash from operations: $-5.033M FY2026-Q2; GAAP. Published target: cash from operations >= -$3.5M per quarter. Target period is not explicitly aligned with this observation. Aug 12, 2026-5,033,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating losses remain controlled near -$2.7M per quarter | Artelo Biosciences focuses on managing operating losses near -$2.7M in Q1 2026. | Broken | operating income falls below -$2.7M per quarter | Operating income: $-2.505M FY2026-Q2; GAAP. Published target: operating income >= -$2.7M per quarter. Target period is not explicitly aligned with this observation. Aug 12, 2026-2,505,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-5.28 → $-47.52 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-07-25 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-07-26 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-07-27 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-07-28 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-07-29 | $-5.28 | $0 | 1 / 1 |
| 2026-07-30 | $-5.28 | $0 | 1 / 1 |
| 2026-07-31 | $-5.28 | $0 | 1 / 1 |
| 2026-08-01 | $-5.28 | $0 | 1 / 1 |
| 2026-08-02 | $-5.28 | $0 | 1 / 1 |
| 2026-08-03 | $-5.28 | $0 | 1 / 1 |
| 2026-08-04 | $-5.28 | $0 | 1 / 1 |
| 2026-08-05 | $-5.28 | $0 | 1 / 1 |
| 2026-08-06 | $-5.28 | $0 | 1 / 1 |
| 2026-08-07 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-08 | $-5.28 | $0 | 1 / 1 |
| 2026-08-09 | $-5.28 | $0 | 1 / 1 |
| 2026-08-10 | $-5.28 | $0 | 1 / 1 |
| 2026-08-11 | $-5.28 | $0 | 1 / 1 |
| 2026-08-12 | $-5.28 | $0 | 1 / 1 |
| 2026-08-13 | $-5.28 | $0 | 1 / 1 |
| 2026-08-14 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-15 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-16 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-17 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-18 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-19 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-20 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-21 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-22 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-23 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-24 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-25 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-26 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-27 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-28 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-29 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-30 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-08-31 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-09-01 | $-5.28 | $49,287,000 | 1 / 1 |
| 2026-09-02 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-03 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-04 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-05 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-06 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-07 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-08 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-09 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-10 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-11 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-12 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-13 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-14 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-15 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-16 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-17 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-18 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-19 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-20 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-21 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-22 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-23 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-24 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-25 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-26 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-27 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-28 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-29 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-09-30 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-01 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-02 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-03 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-04 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-05 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-06 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-07 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-08 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-09 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-10 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-11 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-12 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-13 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-14 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-15 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-16 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-17 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-18 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-19 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-20 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-21 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-22 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-23 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-24 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-25 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-26 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-27 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-28 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-29 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-30 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-10-31 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-11-01 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-11-02 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-11-03 | $-47.52 | $49,287,000 | 1 / 1 |
| 2026-11-04 | $-47.52 | $49,287,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.